AI

Also, Olympus has come up with the third-generation Visera Elite surgical visualisation platform for endoscopic procedures.

The Indian derma startup is also working to optimise its platform.

The solution screens for plus disease, which is associated with severe ROP.

Individuals are also less likely to trust AI-suggested interventions than those recommended by humans.

The new tool measures the diameter of the ventricles of the heart to provide the ratio of the maximum right ventricle diameter compared with the left ventricle. That can help indicate pulmonary embolism severity.

The company will maintain its patent right for the technology.

Also, Lunit has received Taiwan's approval for its AI mammography solution.

The AI model still has a modest prediction accuracy and is slated for a wider clinical trial soon.

It will use its fresh funds to complete a multi-site validation study across eight Asia-Pacific markets.

This comes after it launched its CDI tool called DxPrime in June.